Le et colleagues reported the case of a female patient with no smoking history, affected by SCLC harboring EGFR delL747_P753insS, who received erlotinib 150 mg/day after progression to standard platinum-based chemotherapy. The gene discussed is EGFR; the disease is small cell lung carcinoma.